Aurobindo Pharma's strong financial performance in Q4FY24 and FY24, driven by revenue growth and net profit increase, was supported by market expansions, compliance enhancements, and regulatory adherence. The company's commitment to growth and operational stability remains firm.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/fnE1uDa
https://ift.tt/6ThHMlf
0 Comments